Garadacimab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Current and future therapies for bradykinin-mediated angioedema
Journal: Dermatologie (Heidelberg, Germany)
Published: May 27, 2026
Monoclonal antibodies in the management of hereditary angioedema.
Journal: Expert opinion on biological therapy
Published: April 28, 2026
Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.
Journal: International journal of molecular sciences
Published: February 26, 2026
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.
Journal: Advances in therapy
Published: February 23, 2026
Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema".
Journal: Drugs in R&D
Published: January 12, 2026
Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026
Garadacimab-gxii-A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review.
Journal: The Annals of pharmacotherapy
Published: January 07, 2026
Garadacimab (Andembry) for hereditary angioedema prophylaxis.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway.
Journal: Annals of medicine and surgery (2012)
Published: August 10, 2025
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.
Journal: Journal of comparative effectiveness research
Published: July 10, 2025
Last Updated: 09/26/2026